Biofrontera Inc. in Talks for Major Changes in Cooperation with Biofrontera AG

Reuters

06-12

<a href="https://laohu8.com/S/BFRI">Biofrontera Inc</a>. in Talks for Major Changes in Cooperation with <a href="https://laohu8.com/S/BFFTF">Biofrontera AG</a>

WOBURN, Mass. (June 11, 2025) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in photodynamic therapy, has confirmed ongoing negotiations with Biofrontera AG regarding potential fundamental changes in their cooperation. The discussions involve either a possible merger of the two companies or adjustments to their existing license and supply agreement. These adjustments could lead to a transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and potentially reduce the transfer price for Biofrontera Inc.'s licensed products sold in the US. The terms of the agreement are still being negotiated and have not yet been finalized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014674), on June 11, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542053478"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542053478\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542053478?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-12 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542053478","market":"nz","top_or_hot":-1,"title":"Biofrontera Inc. in Talks for Major Changes in Cooperation with Biofrontera AG","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. in Talks for Major Changes in Cooperation with <a href=\"https://laohu8.com/S/BFFTF\">Biofrontera AG</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WOBURN, Mass. (June 11, 2025) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in photodynamic therapy, has confirmed ongoing negotiations with Biofrontera AG regarding potential fundamental changes in their cooperation. The discussions involve either a possible merger of the two companies or adjustments to their existing license and supply agreement. These adjustments could lead to a transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and potentially reduce the transfer price for Biofrontera Inc.'s licensed products sold in the US. The terms of the agreement are still being negotiated and have not yet been finalized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014674), on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biofrontera Inc. in Talks for Major Changes in Cooperation with Biofrontera AG</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiofrontera Inc. in Talks for Major Changes in Cooperation with Biofrontera AG\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-12 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. in Talks for Major Changes in Cooperation with <a href=\"https://laohu8.com/S/BFFTF\">Biofrontera AG</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WOBURN, Mass. (June 11, 2025) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in photodynamic therapy, has confirmed ongoing negotiations with Biofrontera AG regarding potential fundamental changes in their cooperation. The discussions involve either a possible merger of the two companies or adjustments to their existing license and supply agreement. These adjustments could lead to a transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and potentially reduce the transfer price for Biofrontera Inc.'s licensed products sold in the US. The terms of the agreement are still being negotiated and have not yet been finalized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014674), on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL6GKZBl:1","article_id":"2542053478","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542053478","pubTimestamp":1749668451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"WOBURN, Mass.  - Biofrontera Inc. , a biopharmaceutical company specializing in photodynamic therapy, has confirmed ongoing negotiations with Biofrontera AG regarding potential fundamental changes in their cooperation. The discussions involve either a possible merger of the two companies or adjustments to their existing license and supply agreement. These adjustments could lead to a transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and potentially reduce the transfer price for Biofrontera Inc.'s licensed products sold in the US. The terms of the agreement are still being negotiated and have not yet been finalized.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Biofrontera Inc.正在就与Biofrontera AG合作的重大变化进行谈判","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFRI":0.9},"content_text":"Biofrontera Inc. in Talks for Major Changes in Cooperation with Biofrontera AG\n\n\n        WOBURN, Mass. (June 11, 2025) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in photodynamic therapy, has confirmed ongoing negotiations with Biofrontera AG regarding potential fundamental changes in their cooperation. The discussions involve either a possible merger of the two companies or adjustments to their existing license and supply agreement. These adjustments could lead to a transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and potentially reduce the transfer price for Biofrontera Inc.'s licensed products sold in the US. The terms of the agreement are still being negotiated and have not yet been finalized.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014674), on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}